(-0.46%) 5 043.50 points
(-0.22%) 37 908 points
(-0.73%) 17 444 points
(-1.92%) $80.36
(-2.46%) $1.942
(0.09%) $2 304.90
(0.36%) $26.75
(1.26%) $960.15
(-0.02%) $0.937
(-0.01%) $11.09
(0.07%) $0.801
(0.01%) $93.46
1.52% ¥ 3 477.00
Live Chart Being Loaded With Signals
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation...
Stats | |
---|---|
Dagens volum | 128 400 |
Gjennomsnittsvolum | 123 820 |
Markedsverdi | 131.67B |
EPS | ¥0 ( 2024-02-05 ) |
Neste inntjeningsdato | ( ¥0 ) 2024-05-07 |
Last Dividend | ¥75.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 44.33 |
ATR14 | ¥0.906 (0.03%) |
Volum Korrelasjon
Kaken Pharmaceutical Co., Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Kaken Pharmaceutical Co., Korrelasjon - Valuta/Råvare
Kaken Pharmaceutical Co., Økonomi
Annual | 2022 |
Omsetning: | ¥72.98B |
Bruttogevinst: | ¥39.56B (54.20 %) |
EPS: | ¥144.79 |
FY | 2022 |
Omsetning: | ¥72.98B |
Bruttogevinst: | ¥39.56B (54.20 %) |
EPS: | ¥144.79 |
FY | 2022 |
Omsetning: | ¥76.03B |
Bruttogevinst: | ¥41.58B (54.68 %) |
EPS: | ¥251.43 |
FY | 2021 |
Omsetning: | ¥74.98B |
Bruttogevinst: | ¥40.91B (54.56 %) |
EPS: | ¥347.37 |
Financial Reports:
No articles found.
Kaken Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥75.00 (N/A) |
¥0 (N/A) |
¥75.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.50 | 2001-03-27 |
Last Dividend | ¥75.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥1 874.70 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.32 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.36 | |
Div. Directional Score | 6.18 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9067.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7952.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7184.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6428.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5408.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4430.T | Ex Dividend Knight | 2024-05-30 | Annually | 0 | 0.00% | |
3608.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
2813.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
1433.T | Ex Dividend Junior | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
9735.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0411 | 1.500 | 9.18 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0176 | 1.200 | 9.41 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0214 | 1.500 | -0.873 | -1.310 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0229 | -1.500 | 9.62 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 248.72 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.539 | 1.000 | 4.35 | 4.35 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0621 | 1.000 | -0.758 | -0.758 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.429 | 1.000 | 3.17 | 3.17 | [0.2 - 2] |
assetTurnoverTTM | 0.428 | 0.800 | -0.478 | -0.382 | [0.5 - 2] |
Total Score | 10.01 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 44.43 | 1.000 | 5.61 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0214 | 2.50 | -0.561 | -1.310 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.31 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.048 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0763 | 1.000 | -0.592 | 0 | [0.1 - 0.5] |
Total Score | 2.36 |
Kaken Pharmaceutical Co.,
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.